Skip to main content
Year archive

Vivesto — 2025 filings

All 23 regulatory filings released by Vivesto (VIVE) in 2025, sourced directly from the official regulator.

23 Filings
2025 Period
2025 filings (23)
Filing Released Lang
Kommuniké från extra bolagsstämma i Vivesto AB
AGM Information
2025-12-22 Swedish
Report from Extraordinary General Meeting in Vivesto AB
Declaration of Voting Results & Voting Rights Announcements
2025-12-22 English
Notice of Extraordinary General Meeting in Vivesto AB
Regulatory Filings
2025-11-20 English
Kallelse till extra bolagsstämma i Vivesto AB
Regulatory Filings
2025-11-20 Swedish
Vivesto resolves on a fully secured rights issue of approximately SEK 53.8 million, subject to approval by an Extraordinary General Meeting
Regulatory Filings
2025-11-20 English
Vivesto beslutar om en fullt säkerställd företrädesemission om cirka 53,8 MSEK villkorat av godkännande från extra bolagsstämma
Regulatory Filings
2025-11-20 Swedish
Interim / Quarterly Report 2025
Interim / Quarterly Report
2025-11-20 Swedish
Vivesto rapporterar positiva interimsresultat från pilotstudie med Paccal Vet i hundar
Regulatory Filings
2025-11-07 Swedish
Vivesto reports positive interim results for Paccal Vet pilot study in dogs
Regulatory Filings
2025-11-07 English
Valberedning utsedd inför Vivestos årsstämma 2026
Board/Management Information
2025-11-07 Swedish
Nomination Committee appointed for the Annual General Meeting 2026 in Vivesto
Board/Management Information
2025-11-07 English
Interim / Quarterly Report 2025
Interim / Quarterly Report H1 2025
2025-08-12 Swedish
Kommuniké från årsstämma i Vivesto AB
AGM Information
2025-05-08 Swedish
Report from Annual General Meeting in Vivesto AB
AGM Information
2025-05-08 English
Interim / Quarterly Report 2025
Interim / Quarterly Report Q1 2025
2025-05-08 Swedish
Annual Report 2024
Annual Report FY 2024
2025-04-08 Swedish
Kallelse till årsstämma i Vivesto AB
Proxy Solicitation & Information Statement
2025-04-08 Swedish
Notice of Annual General Meeting in Vivesto AB
Proxy Solicitation & Information Statement
2025-04-08 English
Vivesto tecknar avtal med Kazia Therapeutics om att förvärva fullständiga rättigheter till Cantrixil
M&A Activity
2025-03-31 Swedish
Vivesto signs deal with Kazia Therapeutics to acquire full Cantrixil rights
M&A Activity
2025-03-31 English
Vivesto licenses Apealea to China’s Zhida Pharmaceutical
M&A Activity
2025-03-18 English
Vivesto utlicensierar Apealea till kinesiska Zhida Pharmaceutical
Regulatory Filings
2025-03-18 Swedish
Audit Report / Information 2024
Audit Report / Information FY 2024
2025-02-20 Swedish